Pharmaceutical - Lundbeck

Filter

Current filters:

Lundbeck

Popular Filters

1 to 25 of 100 results

Lundbeck launches Brintellix in Denmark

Lundbeck launches Brintellix in Denmark

16-09-2014

Danish CNS drug specialist Lundbeck is debutting its new antidepressant Brintellix (vortioxetine) in…

BrintellixCNS DiseasesDenmarkLundbeckMarkets & MarketingPharmaceutical

Lundbeck launches Northera in USA

Lundbeck launches Northera in USA

02-09-2014

Danish CNS specialist Lundbeck said today that Northera (droxidopa) capsules for oral use are now available…

Chelsea TherapeuticsLundbeckMarkets & MarketingNeurologicalNortheraPharmaceuticalUSA

Lundbeck and Otsuka file for US approval of brexpiprazole

Lundbeck and Otsuka file for US approval of brexpiprazole

14-07-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka have submitted a New Drug Application…

brexpiprazoleLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalPiperidinesRegulationUSA

UK’s NICE backs Lundbeck drug for alcohol dependence

UK’s NICE backs Lundbeck drug for alcohol dependence

10-07-2014

In new draft guidance, the UK drug watchdog the National Institute for Health and Care Excellence (NICE)…

LundbeckNeurologicalPharmaceuticalPricingRegulationSelincroUK

Lundbeck's desmoteplase misses primary endpoint in Ph III stroke study

28-06-2014

Danish CNS specialist Lundbeck (LUND: CO) released disappointing initial headline conclusions from DIAS-3,…

desmoteplaseLundbeckNeurologicalPharmaceutical

US psychiatrists’ views on prescribing Otsuka/Lundbeck’s brexpiprazole

26-06-2014

Surveyed US psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant…

brexpiprazoleBrintellixLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Brintellix meets primary efficacy end-point in depression study

Brintellix meets primary efficacy end-point in depression study

26-06-2014

Danish CNS drug specialist Lundbeck has announced results of the SOLUTION trial conducted in Asian patients…

BrintellixDenmarkLundbeckNeurologicalPharmaceuticalResearch

Lundbeck to complete Chelsea Thera acquisition today

Lundbeck to complete Chelsea Thera acquisition today

23-06-2014

Danish CNS specialist Lundbeck says that it has completed the tender offer to buy all of the outstanding…

Chelsea TherapeuticsLundbeckMergers & AcquisitionsNeurologicalNortheraPharmaceutical

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

17-06-2014

Danish CSN drug specialist Lundbeck has presented results about sexual functioning from a head-to-head…

BrintellixEscitalopram OxalateLundbeckMen's HealthNeurologicalPharmaceuticalResearch

Lundbeck’s Brintellix shows efficacy in cognitive function study

Lundbeck’s Brintellix shows efficacy in cognitive function study

16-06-2014

Danish CNS drug specialist Lundbeck has announced results from the CONNECT study showing that Brintellix…

BrintellixDenmarkDepressionLundbeckNeurologicalPharmaceuticalResearch

Lundbeck partners with academia to advance understanding of Parkinson’s disease

15-05-2014

Danish CNS drug specialist Lundbeck says it is involved in new research with a UK university on Parkinson's…

LundbeckNeurologicalPharmaceuticalResearch

Lundbeck 1st-qtr sales and profits slump on generic competition

Lundbeck 1st-qtr sales and profits slump on generic competition

07-05-2014

Danish CNS drug specialist Lundbeck took a significant hit from generic competition in the first quarter…

FinancialLundbeckNeurologicalPharmaceutical

US FDA accepts for review Otsuka and Lundbeck’s sNDA for Abilify Maintena

US FDA accepts for review Otsuka and Lundbeck’s sNDA for Abilify Maintena

30-04-2014

Danish CNS specialist Lundbeck and the US subsidiary of Japan’s Otsuka Pharmaceutical revealed that…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalRegulationUSA

Lundbeck partners with Nanomerics for drug delivery collaboration

Lundbeck partners with Nanomerics for drug delivery collaboration

30-04-2014

UK-based drug delivery company Nanomerics, a spin out of the University College London, has announced…

Brain cancerBrain tumorCNS DiseasesDementiaLundbeckMedicineNeurologicalPharmaceuticalResearchUKUniversity College London

Abilify Maintena cuts hospitalization rates for patients with schizophrenia vs oral antipsychotics

07-04-2014

Danish CNS drug specialist Lundbeck and partner Japanese drugmaker Otsuka Pharmaceutical today announced…

Abilify MaintenaLundbeckNeurologicalOtsukaPharmaceuticalResearch

Lundbeck to enter a partnership with Lieber Institute

Lundbeck to enter a partnership with Lieber Institute

01-04-2014

Danish CNS specialist Lundbeck, together with a number of other companies, is now entering into a collaboration…

LundbeckNeurologicalPharmaceuticalResearch

Lundbeck and Otsuka update on European launch of Abilify Maintena

Lundbeck and Otsuka update on European launch of Abilify Maintena

17-03-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka Pharmaceutical’s European subsidiary…

Abilify MaintenaEuropeLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Pharma Summit: Rethinking the future – new business models for pharma

Pharma Summit: Rethinking the future – new business models for pharma

14-03-2014

The way pharma works needs to change with an increasing focus on collaborations, sharing data and access…

HealthcareInterviewsLundbeckPfizerPharmaceuticalPricingUK

Lundbeck releases positive results from six-year Onfi study

Lundbeck releases positive results from six-year Onfi study

12-03-2014

Danish CNS drug specialist Lundbeck has published results from a long-term, open-label extension study…

DenmarkLundbeckNeurologicalOnfiPharmaceuticalResearch

FDA accepts Lundbeck NDA for IV carbamazepine

FDA accepts Lundbeck NDA for IV carbamazepine

10-03-2014

The US subsidiary of Danish CNS specialist Lundbeck says that the Food and Drug Administration has accepted…

CarbamazepineCarbellaFinancialLigand PharmaceuticalsLundbeckNeurologicalNorth AmericaPharmaceuticalRegulationUSA

Lundbeck raises $1.2 million by increasing share capital

Lundbeck raises $1.2 million by increasing share capital

19-02-2014

Danish CNS drug specialist Lundbeck will raise 6,753,283 Danish kroner ($1,242,714) by increasing its…

DenmarkFinancialLundbeckPharmaceutical

New products boost Lundbeck’s 2013 performance

New products boost Lundbeck’s 2013 performance

06-02-2014

Danish CNS drug specialist Lundbeck has reported financials for 2013, showing that revenues increased…

FinancialLundbeckPharmaceutical

Lundbeck and Otsuka’s brexpiprazole shows efficacy in Phase III trial

Lundbeck and Otsuka’s brexpiprazole shows efficacy in Phase III trial

24-01-2014

Danish CNS drug specialist Lundbeck (LUND: CO) and Japanese drug maker Otsuka (TYO: 4768) have revealed…

brexpiprazoleDenmarkLundbeckNeurologicalOtsukaPharmaceuticalResearch

1 to 25 of 100 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top